← Back to Search

Smart ambient bright light for Caregiver

N/A

Recruiting

Led By Ying-Ling Jao, PhD

Research Sponsored by Penn State University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age≥55

Nursing home residency≥3 months

Timeline

Screening 3 weeks

Treatment Varies

Follow Up weeks 1, 3, 5, 7, 9, 11, and 13

Awards & highlights

Study Summary

This trial will test a system that combines natural daylight with LED lights to reduce agitation in people with Alzheimer's Disease & Related Dementias in nursing homes. It will also measure the system's effectiveness, feasibility & fidelity.

Who is the study for?

This trial is for nursing home residents aged 55 or older who have been living in the home for at least three months, speak English, and have a clinical diagnosis of Alzheimer's Disease or related dementia with recent agitation.Check my eligibility

What is being tested?

The study tests a smart ambient bright light (SABL) system designed to mimic natural daylight cycles. It aims to reduce agitation in people with dementia by automatically adjusting indoor lighting based on time and available natural light over four weeks.See study design

What are the potential side effects?

Since this intervention involves environmental lighting adjustments rather than medication, traditional side effects are not expected. However, changes in light may affect sleep patterns or mood.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 55 years old or older.

Select...

I have been living in a nursing home for at least 3 months.

Select...

I have been diagnosed with Alzheimer's Disease or a similar type of dementia.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ weeks 1, 3, 5, 7, 9, 11, and 13

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~weeks 1, 3, 5, 7, 9, 11, and 13

This trial's timeline: 3 weeks for screening, Varies for treatment, and weeks 1, 3, 5, 7, 9, 11, and 13 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in agitation

Change in light level: CS at the facility level

Change in light level: CS at the individual level

+5 more

Secondary outcome measures

Adverse effects.

Affect

Behavioral and Psychological Symptoms of Dementia (BPSD)

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Smart ambient bright lightExperimental Treatment1 Intervention

The smart ambient bright light (SABL) intervention provides auto-controlled, consistent indoor lighting that incorporates natural daylight.

Group II: ControlPlacebo Group1 Intervention

Usual light.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Penn State UniversityLead Sponsor

355 Previous Clinical Trials

125,717 Total Patients Enrolled

Ying-Ling Jao, PhDPrincipal InvestigatorPenn State University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the upper limit of enrollees in this experiment?

"Affirmative. Clinicaltrials.gov clearly displays this clinical trial as actively recruiting, which was initially posted on April 24th 2023 and most recently edited on December 12th 2023. The study is admitting 40 patients across two sites."

Answered by AI

Does this trial currently need more participants?

"Affirmative. Data posted on clinicaltrials.gov confirms that this experiment, initially published April 24th 2023, is actively enrolling participants. 40 individuals must be gathered from two different medical facilities."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Smart Lighting for Nursing Home Residents With Dementia

Ying-Ling Jao RN, PhD, FGSA 2023. "Smart Lighting for Nursing Home Residents With Dementia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05825404.